Table 1.
Characteristics of Participants With Concordant vs Discordant Screening for PA
| Discordant Screen (Positive PA Screen on HS; Negative PA Screen on LS); 44/79 (56%) | Concordant Screen (Positive PA Screen on HS; Positive PA Screen on LS); 35/79 (44%) | P Value | |
|---|---|---|---|
| Age (y) | 49.4 ± 8.1 | 49.6 ± 6.7 | .920 |
| Caucasian race (%) | 90 | 62 | .002 |
| BMI (kg/m2) | 28.4 ± 3.9 | 28.7 ± 3.5 | .762 |
| Gender (% male) | 64 | 66 | .850 |
| SBP on HS (mm Hg) | 145.8 ± 21.6 | 157.2 ± 23.2 | .030 |
| SBP on LS (mm Hg) | 127.2 ± 16.3 | 140.2 ± 21.0 | .005 |
| ARR on HS | 54.5 ± 49.2 | 77.2 ± 36.8 | .008a |
| ARR on LS | 12.6 ± 5.7 | 54.3 ± 38.2 | <.001a |
| HS plasma potassium (mmol/L) | 4.11 ± 0.3 | 3.96 ± 0.3 | .039 |
| LS plasma potassium (mmol/L) | 4.18 ± 0.3 | 4.20 ± 0.2 | .955 |
| HS aldosterone (ng/dL) | 11.1 ± 5.2 | 10.3 ± 4.1 | .755 |
| LS aldosterone (ng/dL) | 19.6 ± 12.3 | 17.0 ± 8.5 | .567 |
| HS PRA (ng/mL · h) | 0.25 ± 0.1 | 0.16 ± 0.1 | .001a |
| LS PRA (ng/mL · h) | 2.03 ± 1.9 | 0.44 ± 0.3 | <.001a |
| HS urinary sodium (24 h mmol) | 237.2 ± 61.3 | 242.3 ± 58.5 | .708 |
| LS urinary sodium (24 h mmol) | 14.2 ± 9.9 | 16.7 ± 7.4 | .246 |
| HS urinary aldosterone (μg/24 h) | 14.7 ± 7.0 | 14.9 ± 6.6 | .906 |
| LS urinary aldosterone (μg/24 h) | 38.6 ± 22.4 | 24.4 ± 10.9 | .001 |
| Aldosterone fold changes (HS to LS) (magnitude and %) | 1.92 ± 1.0 (92%) | 1.77 ± 0.9 (77%) | .508 |
| PRA fold changes (HS to LS) (magnitude and %) | 10.9 ± 11.8 (+909%) | 3.5 ± 4.9 (+250%) | .006a |
Data as mean ± SD, except as noted. Positive screening: ARR > 20, aldosterone > 6 ng/dL, PRA < 1 ng/mL · h.
a
Boostrapped.